Safety and management of niraparib monotherapy in ovarian cancer clinical trials | International Journal of Gynecologic Cancer
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Niraparib in the PRIMA Trial
First-line niraparib is associated with improvement in QA-PFS and QA-TWiST
Efficacy | ZEJULA (niraparib) for HCPs
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer | Targeted Oncology
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab - ScienceDirect
Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study | Future Oncology
Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study - Gynecologic Oncology
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) -
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
Efficacy | ZEJULA (niraparib) for HCPs
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Efficacy | ZEJULA (niraparib) for HCPs
Current Oncology | Free Full-Text | A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial - Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana
Inhibidores de PARP en primera línea de cáncer de ovario | PPT
